CAMBRIDGE, Mass., April 8, 2026—Anumana, Inc., a leader in cardiovascular AI, today announced U.S. Food and Drug Administration (FDA) clearance of its ECG-AI® algorithm for cardiac amyloidosis (CA) – the…

CAMBRIDGE, Mass. – March 28, 2026 – Anumana, a leader in cardiovascular AI, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its pulmonary hypertension (PH) algorithm, an AI-enabled…

Recognition highlights Anumana’s leadership in AI-driven cardiovascular detection and clinical decision support  CAMBRIDGE, Mass., March 24, 2026—Anumana, a leader in AI-powered cardiovascular detection algorithms, today announced it has been named…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anumana Inc., a leader in AI-powered cardiovascular detection algorithms, today announced the appointment of Kevin Ballinger and Jean-Luc Butel to its Board of Directors. In their roles, Ballinger and…

Simultaneous publication in Journal of the American College of Cardiology demonstrates impact of ECG-AI on heart failure risk assessment. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anumana, a leader in AI-powered cardiovascular diagnostics, today announced…

Company to present four studies, including a late-breaking featured science presentation, and host interactive experiences demonstrating AI’s role in cardiovascular care

Building on our previous discussion of imbalanced regression, we now turn to another critical challenge: uncertainty estimation. While addressing data imbalance helps models pay attention to rare cases, we must also…

Anumana's FDA-cleared LEF algorithm becomes first certified third-party solution available through Philips’ ECG ecosystem

Clinical AI systems often include automated analysis of medical time series, such as electrocardiogram (ECG), to serve as valuable diagnostic decision support tools. While many cardiovascular diseases are traditionally measured…

New investment fuels growth of ECG-AI platform and development of perioperative AI capabilities